New diabetes shot could cut injections to once a month
NCT ID NCT07563699
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new, long-acting form of semaglutide (a diabetes drug) that is given once every four weeks instead of weekly. The goal is to see if it is safe and works well for controlling blood sugar and weight in 24 adults with type 2 diabetes. Participants must already be on weekly semaglutide and have stable blood sugar levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mapi pharma Investigational Site ISR001
Tel Aviv, 6423906, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could meal kits and text messages help curb diabetes in Food-Insecure communities?
- Walking downhill may boost heart health and strength in type 2 diabetes
- Could a simple supplement soothe diabetic nerve damage?
- Can family coaching cut diabetes risk? pilot study targets high-risk communities
- Home workouts via smartphone could help tame type 2 diabetes
- Can a chat with a nurse help control blood pressure and blood sugar?